Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

ALG-001075, the parent of pevifoscorvir sodium, exhibits potent in vitro antiviral properties compared to other HBV capsid assembly modulators in clinical development

Thursday, May 28, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: ALG-001075, a promising antiviral agent, has demonstrated strong in vitro efficacy against HBV compared to other drugs in development. This positions it favorably in the ongoing fight against chronic HBV infection. The article highlights its potential as a significant player in the treatment landscape.
Price reaction · baseline $5.6 (2026-05-27 close) · hit pre-market · 1 other ALGS headline(s) in the window, move may be shared
day 0 close · peak
+3.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • ALG-001075 shows potent antiviral properties.
  • It compares favorably to other HBV capsid assembly modulators.
  • The drug is in clinical development, indicating progress.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-001075?

ALG-001075 is an antiviral agent showing potent activity against HBV.

How does ALG-001075 compare to other HBV treatments?

It exhibits stronger in vitro antiviral properties than other HBV capsid assembly modulators.

Is ALG-001075 currently in development?

Yes, ALG-001075 is in clinical development for chronic HBV infection.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-001075 HBV antiviral clinical development pevifoscorvir sodium
Last updated: May 28, 2026

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →